# NICU: Dinoprostone (Prostaglandin E2)

Reference No: CH PH N 23

Presentation:	Reference NO: CH PH N 23							
Presentation:	0.75ml ampoule containing a 1mg/ml dinoprostone. Stored a refrigerator.							
Indication:	To maintain the patency of the ductus arteriosus							
Dose:	<ul> <li>Initially 5 nanograms/kg/minute         <ul> <li>increase in steps of 5 nanograms/kg/minute as required</li> <li>usual maximum 20 nanograms/kg/minute</li> <li>doses up to 100 nanograms/kg/minute have been used but are associated with increased side-effects</li> </ul> </li> <li>WHERE POSSIBLE, IT IS RECOMMENDED THAT THERAPY IS STARTED OR STOPPED ONLY ON THE ADVICE OF A CARDIOLOGIST</li> </ul>							
Route of	Continuous IV infusion only via SMART pump.							
administration:	Prostaglandin E2 should <u>never</u> be given as a bolus injection.							
Instructions for preparation and	Make an infusion of <b>1 microgram per ml</b> :							
administration: Prescribing	<ol> <li>Measure 0.5ml of 1mg/ml dinoprostone injection (500 micrograms)</li> <li>Add this to 500ml glucose 5% or sodium chloride 0.9%</li> <li>SHAKE THE BAG WELL to ensure thorough mixing. This solution contains 1 microgram/ml</li> <li>Withdraw 50ml from the bag into a luer lock syringe and infuse using a syringe pump</li> <li>Rate of infusion (ml/hour) = 0.06 X Weight (kg) X Dose (nanograms/kg/minute)</li> <li>Infusions should be maintained at the lowest dose and for the shortest time required to achieve the desired clinical effect.</li> <li>The calculated infusion rate should be rounded to the nearest 0.1ml</li> <li>QHB- Prescribe on Meditech</li> </ol>							
	RDH-       Prescribe on paper chart         Example prescription for a 2.5 kg neonate:         Prescribe standard concentration of 1 microgram per mL							
	Drug	proctopo	Drug amoun		Diluent	co 5%	Total volume (ml)	Route IV
	Start date	prostone Drug concentra		rograms		se 5% Iin	50ml Max	Name, Sig, Bleep
	22/5/23	1microgra	•	Dose/kg/time	5 nanograi		20 nanograms/kg/min	A.Doctor
	Pharm			ml/hr	-	75	3	#1234
Directions for administration via SMART pump	<ul> <li>Load Syringe, prime line using the pump for accurate dosing.</li> <li>Open 'NICU' folder then open 'dinoPROstone' programme.</li> <li>Enter Babys weight in kg and confirm</li> <li>Enter the dose in nanograms/kg/min</li> <li>Visually confirm the rate (ml/h) against the prescribed dose (nanograms/kg/min)</li> <li>Perform STOP moment with medical team (Pump against prescription)</li> <li>Connect to Baby</li> <li>Press start button</li> </ul>							

Known	See separate compatibility chart.				
compatibility					
issues					
Side-effects	If apnoeas, bradycardia or severe hypotension occur:				
	Temporarily discontinue infusion (intubation and ventilation may be necessary) and restart				
	infusion with caution at a reduced dose.				
	If pyrexia occurs:				
	Reduce incubator temperature.				
Additional	Discard solution after 24 hours.				
Comments:	Monitor heart rate, blood pressure (in the arm and leg), respiratory rate, urine output,				
	temperature and blood gases.				
	Use with caution if history of haemorrhage.				
	Dinoprostone should be avoided in active renal or hepatic disease. Avoid in hyaline membrane				
	disease (in neonates)				
	Use caution when handling to avoid contact with the skin. Wash hands thoroughly after				
	preparation				

Note: The contents of this monograph should be read in conjunction with information available in the BNFC and Medusa

### **References:**

British National Formulary for Children, accessed via Last accessed: 01/12/23

Medicines for Children, 2003 Last accessed: 01/12/23

Medusa Injectable Medicines Guide - Display - Dinoprostone - Intravenous - Version 7 - IVGuideDisplayMain.asp (medusaimg.nhs.uk). Accessed 01/12/23

SPC, Prostin E2 Sterile Solution 1mg/ml Intravenous, accessed via <u>www.medicines.org.uk</u> Last accessed: 01/12/23

## **Document control sheet**

GUIDELINE NUMBER	
AREA IN WHICH THIS MONOGRAPH APPLIES	NICU

DIVISIONAL AUTHORISATION				
GROUP	DATE			
Paediatric monograph review group				

AUTHORS				
Author	Position	Date		
Written by:	Mustafa Mohamed, Clinical Pharmacist	December 2016		
Checked by:	Lisa Taylor, Specialist Paediatric Pharmacist	December 2016		

#### If review:

	Position	Date
Reviewed by:	Harriet Hughes	November 2019
	Advanced Pharmacist, Women's &	
Name	Children's	
Updated by:	Ellie Cheale	December 2023
Checked by:	Lamia Ahmed	December 2023
	Advanced Pharmacist Women's &	
	Children's	

## Change history:

Changes Reference	Change details	Date
1	Added QHB prescribing instructions	December 2023
2	<ul> <li>Changed preparation instructions ***</li> <li>Amended minimum rate of infusion to 0.8ml to correlate to rounding instructions.</li> <li>Handling instructions added</li> </ul>	December 2023